{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncologic+Disorders&page=23",
    "query": {
      "condition": "Oncologic Disorders",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 752,
    "total_pages": 76,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncologic+Disorders&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncologic+Disorders&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T22:23:08.821Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07501663",
      "title": "Optimizing Integrative Oncology Approaches to Address Chemotherapy-induced Peripheral Neuropathy in Gastrointestinal (GI) Cancer Patients: A SMART Pilot Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "Tai Chi/Qi Gong",
          "type": "BEHAVIORAL"
        },
        {
          "name": "α- Lipoic acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Acupuncture",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DIETARY_SUPPLEMENT",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-01-20",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-23T22:23:08.821Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07501663"
    },
    {
      "nct_id": "NCT02986152",
      "title": "Cancer Distress Coach Mobile App Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Posttraumatic Stress Disorder",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Cancer Distress Coach Mobile App",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 569,
      "start_date": "2017-06-01",
      "completion_date": "2019-04-13",
      "has_results": false,
      "last_update_posted_date": "2019-11-26",
      "last_synced_at": "2026-10-23T22:23:08.821Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02986152"
    },
    {
      "nct_id": "NCT04150965",
      "title": "Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Relapsed Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elotuzumab, pomalidomide, dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Anti-LAG-3",
          "type": "DRUG"
        },
        {
          "name": "Anti-LAG-3 + Pomalidimide + Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Anti-TIGIT",
          "type": "DRUG"
        },
        {
          "name": "Anti-TIGIT + Pomalidimide + Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Multiple Myeloma Research Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-07-10",
      "completion_date": "2024-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-10-23T22:23:08.821Z",
      "location_count": 10,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04150965"
    },
    {
      "nct_id": "NCT04306900",
      "title": "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "TTX-030, budigalimab and mFOLFOX6",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, budigalimab and docetaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030 and mFOLFOX6",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030 and budigalimab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, budigalimab, nab-paclitaxel and gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030 and pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, nab-paclitaxel and gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Budigalimab and mFOLFOX6",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Trishula Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 185,
      "start_date": "2020-03-30",
      "completion_date": "2024-03-27",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-10-23T22:23:08.821Z",
      "location_count": 26,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04306900"
    },
    {
      "nct_id": "NCT07076498",
      "title": "Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "M032",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "36 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "36 Months and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-04-23",
      "completion_date": "2031-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-23T22:23:08.821Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07076498"
    },
    {
      "nct_id": "NCT02847728",
      "title": "Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma",
        "Lung Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1189,
      "start_date": "2016-07-28",
      "completion_date": "2024-03-31",
      "has_results": false,
      "last_update_posted_date": "2024-06-03",
      "last_synced_at": "2026-10-23T22:23:08.821Z",
      "location_count": 12,
      "location_summary": "Palm Springs, California • Jacksonville, Florida • Lake City, Florida + 9 more",
      "locations": [
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lake City",
          "state": "Florida"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Alexandria",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02847728"
    },
    {
      "nct_id": "NCT00005892",
      "title": "Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fanconi's Anemia",
        "Myelodysplastic Syndromes",
        "Leukemia, Nonlymphocytic, Acute",
        "Leukemia, Lymphocytic, Acute"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fairview University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "54 Years",
        "sex": "ALL",
        "summary": "0 Years to 54 Years"
      },
      "enrollment_count": null,
      "start_date": "2000-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-23T22:23:08.821Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005892"
    },
    {
      "nct_id": "NCT02012465",
      "title": "Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Diabetes Mellitus, Type 2",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Insulin protocol",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2013-09",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2018-05-07",
      "last_synced_at": "2026-10-23T22:23:08.821Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02012465"
    },
    {
      "nct_id": "NCT03852030",
      "title": "Mind-Body Health in Uro-Oncology: Research Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer",
        "Kidney Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Text or email message",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2012-07",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2023-06-13",
      "last_synced_at": "2026-10-23T22:23:08.821Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Evanston, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03852030"
    },
    {
      "nct_id": "NCT03326752",
      "title": "Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "DV281",
          "type": "DRUG"
        },
        {
          "name": "Breath Actuated Nebulizer",
          "type": "DEVICE"
        },
        {
          "name": "DV281 (RP2D)",
          "type": "DRUG"
        },
        {
          "name": "Approved Anti-PD-1 Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2017-09-20",
      "completion_date": "2019-09-19",
      "has_results": false,
      "last_update_posted_date": "2020-06-17",
      "last_synced_at": "2026-10-23T22:23:08.821Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Santa Monica, California • Minneapolis, Minnesota + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03326752"
    }
  ]
}